Search
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. … [A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663]
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisSynonyms: (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineAcetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalIt is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections. … Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.
Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylamineDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023.
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. … Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamideCalaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalCalaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890].
Categories: Compounds used in a research, industrial, or household settingVibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigationalprevention to become available in the U.S. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]
Pregabalin
go.drugbank.com/drugs/DB00230ApprovedInvestigational[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161] … Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.
Products: Nb-pregabalin, PREGABALINA CÁPSULAS X 300 MGBufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnIt has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. … It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns,
Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use, Topical Products for Joint and Muscular PainSynonyms: 4-Butoxy-N-hydroxybenzeneacetamideTarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigational[L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific … Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.